Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Pulmatrix, Inc. (NASDAQ: PULM).

Full DD Report for PULM

You must become a subscriber to view this report.


Recent News from (NASDAQ: PULM)

Pulmatrix to Present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018
LEXINGTON, Mass. , Aug. 28, 2018 /PRNewswire/ --  Pulmatrix, Inc . (NASDAQ: PULM) will present at the Rodman & Renshaw 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 10:00 AM EDT in the Lotte New York Palace Hotel in New York City . As part of ...
Source: PR Newswire
Date: August, 28 2018 10:00
Pulmatrix reports Q2 results
Pulmatrix (NASDAQ: PULM ): Q2 EPS of -$0.13 More news on: Pulmatrix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 03 2018 09:02
Pulmatrix Reports Q2 2018 Results
LEXINGTON, Mass. , Aug. 3, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. "We are pleased with the preliminary results of the three-part Phase 1/ 1b clinical trial of Pulmazole. The data supports the potential of Pulmazol...
Source: PR Newswire
Date: August, 03 2018 09:00
Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development
LEXINGTON, Mass. , July 23, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the formation of the Clinical Advisory Board (CAB) for Pulmazole...
Source: PR Newswire
Date: July, 23 2018 10:13
Free Technical Research on Riot Blockchain and Three More Biotech Equities
Stock Research Monitor: PRTA, PTCT, and PULM LONDON, UK / ACCESSWIRE / July 20, 2018/ If you want a free Stock Review on RIOT sign up now at www.wallstequities.com/registration . On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 ed...
Source: ACCESSWIRE IA
Date: July, 20 2018 07:20
Pulmatrix's Pulmazole successful in early-stage study; shares up 4%
Pulmatrix ( PULM +3.8% ) is up on average volume on the heels of is announcement of positive data from Part 3 of its Phase 1/1b study of Pulmazole, an inhaled iSPERSE formulation of antifungal med itraconazole for the treatment of allergic bronchopulmonary aspergillosis in asthma patient...
Source: SeekingAlpha
Date: July, 17 2018 10:13
Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
LEXINGTON, Mass. , July 17, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) announced today that all dosing and follow up visits have been completed for Part 3 of the ongoing first-in-human study of Pulmazole (PUR1900) - an inhaled iSPERSE TM formulation of the anti-fungal drug i...
Source: PR Newswire
Date: July, 17 2018 09:00
Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
LEXINGTON, Mass. , June 25, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today top-line results for the ongoing first-in-human study for Pulmaz...
Source: PR Newswire
Date: June, 25 2018 08:30
Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive
Analysis Focus: WMGI Wright Medical Group N.V. ( WMGI ) stock prices climbed +4.46% to $25.78 on the news of its receipt of FDA premarket approval (‘PMA) for Augment. Augment, an injectable bone graft, is a combination product containing human platelet derived growth factor (rhPDGF...
Source: SeekingAlpha
Date: June, 15 2018 10:00
Early-stage study supports value proposition of Pulmatrix's PUR0200; shares ahead 5%
Nano cap Pulmatrix ( PULM +5.1% ) is up on almost triple normal volume in response to results from a Phase 1 clinical trial assessing lead candidate PUR0200 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). More news on: Pulmatrix, Inc., Vectura Group pl...
Source: SeekingAlpha
Date: June, 13 2018 11:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-180.34030.32910.350.3206280,798
2018-12-170.380.3389360.380.33372,284
2018-12-140.3680.36440.380.36216,990
2018-12-130.3820.3508340.3820.34352,486
2018-12-120.3730.370.390.361183,304

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1828,73567,52442.5552Short
2018-12-1716,80047,05335.7044Short
2018-12-1413,73538,17035.9838Short
2018-12-1314,42078,37518.3987Cover
2018-12-125,36027,91019.2046Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PULM.


About Pulmatrix, Inc. (NASDAQ: PULM)

Logo for Pulmatrix, Inc. (NASDAQ: PULM)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $18,561,181 - 05/11/2018
  • Authorized: 100,000,000 - 05/01/2018
  • Issue and Outstanding: 41,927,221 - 05/01/2018

 


Recent Filings from (NASDAQ: PULM)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 12 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 04 2018
Prospectus filed under Rule 424(b)(4)
Filing Type: 424B4Filing Source: edgar
Filing Date: March, 30 2018

 

 


Daily Technical Chart for (NASDAQ: PULM)

Daily Technical Chart for (NASDAQ: PULM)


Stay tuned for daily updates and more on (NASDAQ: PULM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PULM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PULM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PULM and does not buy, sell, or trade any shares of PULM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/